Sector News

Lonza and Bioqube Ventures to scale biologics and small molecules

December 5, 2021
Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

“The discussions with portfolio companies have been initiated, and we intend to create support along with Bioqube’s investment plans and the specific needs of the respective portfolio companies. We are not disclosing the company names at this time,” Pnina Weitz, global head of venture capital business development and relationship management at Lonza tells NutritionInsight.

“Bioqube is dedicated to advancing science in the European ecosystems to develop breakthrough therapies for patients,” says Debora Dumont, co-founder and managing partner, Bioqube Ventures.

This collaboration offers our portfolio companies the opportunity to leverage Lonza’s expertise and its global network, supporting our hands-on approach in building new and successful ventures, she continues.

Impact of the agreement
As a way of a definition, biologics can be composed of sugars, proteins, nucleic acids or complex combinations of these substances, or may be living cells or tissues.

Leveraged by the partnership, Lonza’s technology that decreases risks of developing and manufacturing molecules ranging from monoclonal antibodies, complex proteins, and small molecules to antibody-drug conjugates.

The company states that the holistic approach to drug substance, product development and manufacturing across various platforms simplifies the supply chain, reduces process complexity and allows for shortened development timelines.

“This framework agreement provides Bioqube Ventures and its portfolio companies a range of services for its late discovery and early development needs,” says Weitz.

“Our customized and scalable solutions demonstrate our commitment to enabling emerging biotechs to take their drug candidates to the clinic.”

Tracking Lonza’s previous moves
Previously, Lonza’s joint venture, Bacthera and Chr. Hansen began to supply live biotherapeutic products following Swiss and Danish manufacturing licenses. These products are suitable to address patients with “unmet medical needs.”

Additionally, Bacthera and Seres Therapeutics partnered to manufacture the “first” live biotherapeutic product, SER-109, Seres’ lead product candidate for recurrent Clostridioides difficile infection (rCDI).

In other developments, Lonza’s UC-II collagen was positioned to attract nutraceutical and pharmaceutical customers as it provides a holistic approach for joint health.

By Nicole Kerr


comments closed

Related News

June 22, 2024

Ferring launches online assessment tool, educational platform around male fertility

Life sciences

Because infertility is often branded largely as a women’s issue, many men may be unaware of their own possible role in the matter and may not undergo testing in a timely manner—even though research has shown that men “substantially” contribute to about half of all cases of infertility.

June 22, 2024

Johnson & Johnson blueprints €125M plant upgrade as part of 5-year Italy investment

Life sciences

After plugging nearly 50 million euros into its Italy R&D in the first half of the decade, Johnson & Johnson Innovative Medicine is significantly upping its commitment to the country. Over the next five years, J&J Innovative Medicine, which recently rebranded from Janssen, will plug a projected 580 million euros ($621.7 million) into its Italian business, the company said in a press release.

June 22, 2024

India’s Lupin announces CEO pick for new subsidiary as it moves into the CDMO arena

Life sciences

From vitamin maker to pharmaceutical specialist and now contract manufacturer, India’s Lupin is embarking on a new phase of its corporate journey. Lupin on Monday unveiled its new subsidiary, Lupin Manufacturing Solutions, which is poised to work on the development, production and sale of active pharmaceutical ingredients.

How can we help you?

We're easy to reach